Fresenius Kabi announces FDA approval of SMOFlipid lipid injectable emulsion for paediatric patients requiring parenteral nutrition

Fresenius

24 March 2022 - First and only four-oil lipid injectable emulsion indicated for paediatric parenteral nutrition, including term and preterm neonates.

Fresenius Kabi announced today it has been granted an expanded indication for SMOFlipid lipid injectable emulsion for paediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.

SMOFlipid can be used throughout the continuum of care – from the hospital to home care settings.

Read Fresenius Kabi press release

Michael Wonder

Posted by:

Michael Wonder